Journal of Formulation Science & Bioavailability

Department of formulation and bioavailability, University of Cologne, Germany, Germany

Publications

• Editorial   
  Esketamine Spray Drug to Cure Paralysis
  Author(s): Ziemandonald*
  
  Esketamine drug is employed within the treatment of restrictive depression in adults. In 1997 Esketamine is introduced in medical use and now in March 5th, 2019 it's approved by FDA for the treatment of depression in adults by nasal route. Oneamong good advantage of Nasal Spray is that it'll act faster and potentially help those patients which experience suicidal thoughts more quickly. it's the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and up to some extent it'll also act on dopamine reuptake inhibitor but don't interact with sigma receptor as like ketamine drug. it's a sort of ketamine drug which is approved by FDA in 1970 which having two chemical forms R and S and Esketamine contain on of it and that i .e. S form... Read More»
  

  Abstract PDF